Reset filter
Keywords
Clinical Trial ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

1836 Search results.
Relevance Rating New first Old first

Pathology - Colon and Rectum Carcinoma - Anatomic Pathology Form - 2019345v2.31 - Colon and Rectum Carcinoma - Anatomic Pathology Form

- 1/8/15 - 1 form, 4 itemgroups, 65 items, 1 language
Itemgroups: COLORECTAL: CRF HEADER , COLORECTAL PATHOLOGY: FORM ADMINISTRATION, PATHOLOGY: SURGICAL PATHOLOGY - MACROSCOPIC/GROSS DESCRIPTION, PATHOLOGY: SURGICAL PATHOLOGY - MICROSCOPIC DESCRIPTION
Colon and Rectum Carcinoma - Anatomic Pathology Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99CD59C5-A97A-3FA4-E034-080020C9C0E0

Eligibility Postoperative Ileus NCT02510911

- 6/14/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?; ODM derived from: https://clinicaltrials.gov/show/NCT02510911

Eligibility Colon Cancer NCT00819780

- 12/20/17 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00819780

Eligibility Colon Cancer NCT01003600

- 12/20/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information; ODM derived from: https://clinicaltrials.gov/show/NCT01003600

Eligibility Colon Cancer NCT00890188

- 12/20/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00890188

Eligibility Colon Cancer NCT00411450

- 2/10/17 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT00411450

Eligibility Liver Metastasis NCT00068068

- 10/8/16 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases; ODM derived from: https://clinicaltrials.gov/show/NCT00068068

Eligibility Colon Cancer NCT00695201

- 1/10/16 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00695201

Eligibility Liver Cirrhosis NCT02508623

- 4/27/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices; ODM derived from: https://clinicaltrials.gov/show/NCT02508623

Eligibility Cancer NCT00752570

- 11/10/17 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00752570

Colon cancer (NSABP C-08 NCT00096278) - REGISTRATION FORM Colon cancer (NCT00096278)

- 9/20/21 - 1 form, 3 itemgroups, 64 items, 1 language
Itemgroups: Header, Patient characteristics, Eligibility Checklist
NSABP PROTOCOL C-08: REGISTRATION FORM Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer NCT00096278 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D7F6865F-B506-428D-E034-0003BA12F5E7

Eligibility Liver Carcinoma NCT00791544

- 9/20/21 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00791544

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial